Global Stem Cell Therapies Overview Report 2019: The Highs & Lows, Off-The-Shelf Solutions, New Technologies, and Safety, Efficacy & Logistical ChallengesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Global Stem Cell Therapies Overview Report 2019: The Highs & Lows, Off-The-Shelf Solutions, New Technologies, and Safety, Efficacy & Logistical ChallengesPR NewswireJanuary 8, 2020ReblogShareTweetShareDUBLIN, Jan. 8, 2020 /PRNewswire/ -- The "Highs and Lows of Stem Cell Therapies: Off-The-Shelf Solutions" report has been added to ResearchAndMarkets.com's offering.The report includes:Research and Markets LogoMoreAn overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs) Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic off the shelf solutionsKey Topics Covered Chapter 1 Sources and Characteristics of Stem CellsIntroductionChapter 2 New Technologies Driving Stem Cell DevelopmentAdvances in Cell Culture Advances in Isolation Technologies Advances in Genome ManipulationChapter 3 Safety, Efficacy and Logistical ChallengesToxicity-Related Treatment Issues Logistical ChallengesChapter 4 Off-the-Shelf SolutionsExpanding the Course of Stem Cells More Precise Genomic Manipulation of Cells Reduction in Cell-to-Cell Variation Improved Shelf Life Chapter 5 Companies and Technologies to Watch Athersys Inc. BrainStorm Cell Therapeutics Inc. Caladrius Biosciences Cellular Biomedicine Group Inc. Fate Therapeutics Inc. Gamida Cell Ltd. International Stem Cell Corporation Orgenesis Inc. Pluristem Therapeutics Inc. Sangamo Therapeutics Inc. TheraCell Inc. ThermoGenesis Holdings Vericel Corporation VistaGen Therapeutics Inc. Zelluna Immunotherapy Inc.Chapter 6 ReferencesList of TablesTable 1: Stem Cell SourcesTable 2: Comparison of Stem CellsTable 3: Stem Cell Types Versus Cell PropertiesTable 4: Recent Advances in Genome Modulation TechnologiesTable 5: FDA-Approved Cell-Based TherapiesTable 6: Acute and Delayed Adverse Events Associated with Proven and Unproven Stem Cell-Based InterventionsTable 7: Companies Leading the Field in Cell-Based TherapiesList of FiguresFigure 1: Stem Cell Sources Figure 2: Two-Dimensional Versus Three-Dimensional Cell CultureFigure 3: Schematic of Approaches Used for Three-Dimensional Stem Cell Culture Figure 4: Patient Management Strategies to Decrease Side Effects Related with CAR-T Cell TherapyFor more information about this report visit https://www.researchandmarkets.com/r/15o8p9Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.Media Contact:Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716CisionMoreView original content:http://www.prnewswire.com/news-releases/global-stem-cell-therapies-overview-report-2019-the-highs--lows-off-the-shelf-solutions-new-technologies-and-safety-efficacy--logistical-challenges-300983449.htmlSOURCE Research and MarketsReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoCoronavirus will wipe out corporate profit growth in 2020 and may trigger recession: Goldman SachsYahoo Finance